Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie (prior sponsor, Abbott)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female, 18 years of age or older.
Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas.
May have received prior immunotherapy (including monoclonal antibodies) or vaccine therapies.
Measurable disease, according to RECIST criteria.
Negative pregnancy test (women of childbearing potential only).
Pretreatment laboratory levels that meet specific criteria.
You may not be if
Prior treatment with Volociximab (M200) or inhibitors of α5β1 integrin (antibodies or small molecules) or gemcitabine and other chemotherapeutic regimens.
Known hypersensitivity to murine proteins or chimeric antibodies or other components of the product.
Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of the prior investigational drug (whichever is longer).
Monoclonal antibody therapy within 4 weeks of the first dose of Volociximab.
Central Nervous System (CNS) tumor or metastasis.
History of bleeding disorders within the past year.
Medical conditions that may be exacerbated by bleeding.
